Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
17 hedge funds and large institutions have $328K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 9 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
1.49% more ownership
Funds ownership: 5.91% → 7.41% (+1.5%)
23% less funds holding
Funds holding: 22 → 17 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
64% less capital invested
Capital invested by funds: $899K → $328K (-$571K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$121K |
| 2 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$115K |
| 3 |
Millennium Management
New York
|
+$51K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$43K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$119K |
| 2 |
State Street
Boston,
Massachusetts
|
-$20K |
| 3 |
Jane Street
New York
|
-$18K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$15K |
| 5 |
JSW
Journey Strategic Wealth
Summit,
New Jersey
|
-$13K |
FRTX Hedge Fund Activity: Q3 2022 in Review
17 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2022, worth a combined $328K — down 64% from $899K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FRTX and 4 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Telemetry Investments, adding an estimated $121K. The largest seller was Vanguard Group, cutting an estimated $119K.
- 17 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2022, down from 22 in Q2 2022.
- Funds reported $328K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2022, down 64% quarter-over-quarter.
- 4 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2022 and 9 closed out, a net change of -5 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2022 was Telemetry Investments, an estimated $121K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2022.